Back to top
more

Ono Pharmaceutical Co. (OPHLF)

(Delayed Data from OTC)

$13.36 USD

13.36
298

-1.34 (-9.11%)

Updated Aug 29, 2024 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for OPHLF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Ono Pharmaceutical Co falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 1,412 1,216 1,041 987 924
Receivables 939 847 888 792 707
Notes Receivable 0 0 0 0 0
Inventories 336 332 372 368 303
Other Current Assets 168 160 202 181 139
Total Current Assets 2,854 2,554 2,503 2,328 2,072
Net Property & Equipment 723 802 998 1,070 1,055
Investments & Advances 2,031 2,374 2,247 2,621 2,111
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 282 263 223 316 320
Intangibles 395 512 576 661 611
Deposits & Other Assets 19 25 32 24 26
Total Assets 6,304 6,530 6,579 7,020 6,196
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 419 494 442 368 317
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 152 256 14 179 187
Other Current Liabilities 128 141 110 315 316
Total Current Liabilities 715 910 587 881 840
Mortgages 0 0 0 0 0
Deferred Taxes/Income 7 7 9 10 10
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 27 30 36 36 63
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 794 996 690 993 970
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 120 128 154 163 160
Capital Surplus 120 126 153 162 159
Retained Earnings 5,300 5,253 5,738 5,484 4,826
Other Equity 406 427 507 638 493
Treasury Stock 436 401 665 420 412
Total Shareholder's Equity 5,510 5,534 5,889 6,027 5,226
Total Liabilities & Shareholder's Equity 6,304 6,530 6,579 7,020 6,196
Total Common Equity 5,510 5,534 5,889 6,027 5,226
Shares Outstanding NA 514.10 514.10 NA 514.10
Book Value Per Share -0.06 10.76 11.45 -0.06 10.16

Fiscal Year End for Ono Pharmaceutical Co falls in the month of March.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 1,412 -99,999 974 940
Receivables NA 939 NA 978 902
Notes Receivable NA 0 NA NA 0
Inventories NA 336 NA 335 368
Other Current Assets NA 168 NA 165 171
Total Current Assets NA 2,854 NA 2,451 2,381
Net Property & Equipment NA 723 NA 731 785
Investments & Advances NA 2,031 NA 2,322 2,440
Other Non-Current Assets NA 0 NA NA 0
Deferred Charges NA 282 NA 242 247
Intangibles NA 395 NA 417 493
Deposits & Other Assets NA 19 NA 19 19
Total Assets NA 6,304 NA 6,182 6,365
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 NA NA 0
Accounts Payable NA 419 NA 366 379
Current Portion Long-Term Debt NA 0 NA NA 0
Current Portion Capital Leases NA 0 NA NA 0
Accrued Expenses NA 0 NA NA 0
Income Taxes Payable NA 152 NA 177 81
Other Current Liabilities NA 128 NA 138 191
Total Current Liabilities NA 715 NA 697 668
Mortgages NA 0 NA NA 0
Deferred Taxes/Income NA 7 NA 7 7
Convertible Debt NA 0 NA NA 0
Long-Term Debt NA 0 NA NA 0
Non-Current Capital Leases NA 0 NA NA 0
Other Non-Current Liabilities NA NA 27 29
Minority Interest (Liabilities) NA 0 NA NA 0
Total Liabilities NA 794 NA 777 755
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 NA NA 0
Common Stock (Par) NA 120 NA 120 127
Capital Surplus NA 120 NA 118 125
Retained Earnings NA 5,300 NA 5,295 5,283
Other Equity NA 406 NA 433 470
Treasury Stock NA 436 NA 561 395
Total Shareholder's Equity NA 5,510 NA 5,405 5,610
Total Liabilities & Shareholder's Equity NA 6,304 NA 6,182 6,365
Total Common Equity 0 5,510 0 105,404 5,610
Shares Outstanding NA NA NA NA NA
Book Value Per Share 0.00 -0.06 0.00 -1.05 -0.06